XOMA Royalty (XOMA) Accumulated Expenses (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Accumulated Expenses came in at $3.2 million in Q1 2026, up 162.98% year-on-year from $1.2 million in Q1 2025, and down 67.52% quarter-over-quarter from $9.9 million in Q4 2025.
XOMA Royalty (XOMA) Accumulated Expenses (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Accumulated Expenses across 17 years of filings, most recently posting $3.2 million for Q1 2026.
- Accumulated Expenses for Q1 2026 came in at $3.2 million, up 162.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 162.98% YoY), and the FY2025 annual result was $9.9 million, up 71.85% from the prior year.
- Accumulated Expenses came in at $3.2 million for Q1 2026 at XOMA Royalty, down from $9.9 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $9.9 million in Q4 2025 to a low of $231000.0 in Q1 2022.
- The 5-year median for Accumulated Expenses is $1.3 million (2024), against an average of $2.7 million.
- Across the five-year window, Accumulated Expenses sank 81.67% in 2023 and surged 975.14% in 2024, its largest moves.
- XOMA Royalty's Accumulated Expenses stood at $2.9 million in 2022, then tumbled by 81.67% to $535000.0 in 2023, then soared by 975.14% to $5.8 million in 2024, then surged by 71.85% to $9.9 million in 2025, then plunged by 67.52% to $3.2 million in 2026.
- The last three Accumulated Expenses figures came in at $3.2 million (Q1 2026), $9.9 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 9.89 Mn |
| Sep 30, 2025 | 4.13 Mn |
| Jun 30, 2025 | 5.41 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 535,000.00 |
| Sep 30, 2023 | 902,000.00 |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 304,000.00 |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 1.21 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 231,000.00 |
| Dec 31, 2021 | 525,000.00 |
| Sep 30, 2021 | 1.33 Mn |
| Jun 30, 2021 | 1.06 Mn |